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Abstract 
Aims: The carcinogenesis of ovarian clear cell carcinoma (CCC) has been hypothesized to 
comprise two different pathways: an adenofibroma-carcinoma sequence and an 
endometriosis-carcinoma sequence. However, the difference in the genetic basis of these two 
pathways remains unclear. Recent studies have suggested that an ARID1A mutation and the 
loss of the corresponding protein, BAF250a, are frequent events in CCC. Herein, we 
investigated the difference in the loss of BAF250a expression in adenofibroma-related CCC 
and endometriosis-related CCC.  
Methods and Results: In total, 93 cases of surgically treated CCC were evaluated. The 
presence of adenofibroma and endometriosis associated with carcinoma was determined by 
reviewing hematoxylin and eosin-stained slides for each case. BAF250a expression in 
carcinoma was examined immunohistochemically. The loss of BAF250a expression was 
detected in carcinomas in 50 of 93 (54%) cases, including 5/18 (28%) with adenofibroma 
alone, 30/45 (67%) with endometriosis alone, 8/18 (44%) with both conditions, and 7/12 
(58%) with neither condition. The loss of BAF250a expression was significantly less frequent 
in CCC cases with adenofibroma than in cases with endometriosis (p = 0.01, Fisher’s exact 
test). 
Conclusions: The action of ARID1A in carcinogenesis differs between adenofibroma-related 
CCC and endometriosis-related CCC.  
Introduction 
Adenine-thymine–rich interactive domain 1A (ARID1A) has recently been identified as a 
tumour suppressor gene, which is associated with various human neoplastic lesions, including 
gynaecological cancers.1-5 Genome-wide sequencing analysis has shown approximately 50% 
of ovarian clear cell carcinomas (CCC) and 30% of ovarian endometrioid carcinomas, but 
none in high-grade serous carcinoma, to harbour somatic mutations in ARID1A,2, 3 ARID1A 
encodes BAF250a, a component of the ATP-dependent chromatin remodelling complex 
SWI/SNF, containing BRG1 or BRM,2 which plays a crucial role in cell proliferation and 
differentiation.4-8 Recent studies in mice have shown that ARID1A (BAF250a) promotes the 
growth of ovarian carcinomas by interacting with p534, PTEN9, or PIK3CA.10 The loss of 
BAF250a expression—detected by immunostaining—has recently been shown to be 
significantly correlated with an ARID1A mutation,2,11 and it can therefore be used as a 
surrogate marker.  
 Ovarian CCC is frequently associated with endometriosis and less often with 
adenofibroma. The carcinogenesis pathways of endometriosis-related CCC and 
adenofibroma-related CCC are hypothesized to differ from each other12-14 despite the fact that 
both endometriosis and adenofibroma are occasionally present in association with the same 
CCC concurrently.15-17 The molecular abnormality underlying endometriosis-related CCC has 
been ascribed to the highly inflammatory, stressful environment of an endometriotic lesion, 
leading to the activation of the PTEN-PIK3CA-mTOR pathway.18 However, the molecular 
abnormality underlying adenofibroma-related CCC remains unclear. The present study was 
conducted to investigate differences in the loss of BAF250a expression in adenofibroma-
related CCC and endometriosis-related CCC to clarify the difference in the genetic 
background and carcinogenesis between these two lesions.  
 
Materials and Methods 
Patients and tissue samples 
The Institutional Review Board of Chiba University Graduate School of Medicine approved 
this research protocol (Approval Number 1903, 21 August 2014). Ninety-three patients with 
CCC who were surgically treated between 2000 and 2012 at Chiba University Hospital and 
affiliated hospitals in Chiba, Japan, were included in the study. All available hematoxylin and 
eosin-stained slides of the ovarian tumours were reviewed by two gynaecologic pathologists 
to confirm the histological type of the tumours on the basis of the WHO classification19 and 
for the presence of adenofibroma and/or endometriosis associated with carcinoma. In the 
present study, adenofibroma was defined by the presence of proliferation foci of tubules lined 
by a single layer of tumour cells, with minimal nuclear atypia and a marked stromal 
fibromatous component.15-17 We classified endometriosis into two categories: one with 
endometriotic cyst formation contiguous with or adjacent to CCC, and the other being distant 
from CCC, without endometriotic cyst formation. 
 
Immunohistochemical staining 
Formalin-fixed paraffin-embedded tissue sections (4-μm-thick) were deparaffinized, and 
immunohistochemistry was performed using the antibody against ARID1A (BAF250a) 
(HPA005456, Sigma-Aldrich, Tokyo, Japan) at a dilution of 1:400. Auto-stainer Link48 
(Dako, Tokyo Japan) was used for immunostaining. Antigen retrieval was performed by 
incubating sections in low pH Target Retrieval Solution (Dako) at 98°C for 20 min. 
Immunohistochemical staining was scored using a previously described method.1, 20 The 
percentage of positively stained epithelial cells was scored as 0 (0–9%), 1 (10–25%), 2 (26–
50%), or 3 (51–100%), and the intensity was scored as 0 (undetectable), 1 (weak staining), 2 
(moderate staining), or 3 (strong staining). The total immunostaining score was defined as 
percentage positivity score × staining intensity score and ranged from 0 to 9. We considered 
total immunostaining scores of 0–4 as loss of BAF250a expression and scores of 6 or 9 as 
retained BAF250a expression.  
 
Statistical analysis  
Loss of BAF250a expression in adenofibroma-related CCC was compared with that in 
endometriosis-related CCC using Fisher’s exact test. Logistic regression analysis was used to 
clarify the correlation between adenofibroma and loss of BAF250a expression after adjusting 
for the presence of endometriosis. A survival curve for patients with pT1 was calculated using 
the Kaplan–Meier method and compared by the log-rank test. Statistical analyses were 
performed using the Statistical Package for Social Sciences, version II for Windows (SPSS 
Inc., Chicago, IL, USA); p < 0.05 was considered statistically significant.  
 
Results 
Patient characteristics and associated lesions  
The patients’ characteristics and BAF250a expression status are summarised in Table 1. All 
patients were surgically treated, with no residual tumour. The follow-up period ranged from 
seven months to 150 months, with a median of 60 months. Overall, 86 of 93 patients 
presented with stage pT1, and the remaining 7 presented with pT2 or pT3. Of 93 CCCs, 18 
(19%) were associated with adenofibroma alone, 45 (48%) with endometriosis alone, 18 
(19%) with both components, and 12 (13%) with neither of them. No patient with atypical 
endometriosis was identified. 
 
Loss of BAF250a expression in adenofibroma, endometriosis, and carcinoma 
None of the 80 cases with adenofibroma and/or endometriosis showed a loss of BAF250a 
expression in these components, and all had a total immunostaining score of 9. In contrast, 
the extent of BAF250a immunoreactivity in the carcinomatous component varied with regard 
to staining intensity and the percentage of positive cells (Figure 1). Loss of BAF250a 
expression (score 0–4) was detected in the carcinomatous component in 50 (54%) of 93 
patients, and the breakup is as follows: 45 (52%) of 86 patients with pT1 disease, and 5 
(71%) of 7 patients with pT2/pT3 disease. The difference between the two groups was not 
statistically significant (p = 0.445, Fisher’s exact test). Patients with loss of BAF250a 
expression in CCC included 5 (28%) of 18 with adenofibroma alone, 30 (67%) of 45 with 
endometriosis alone, 8 (44%) of 18 with both adenofibroma and endometriosis, and 7 of 12 
(58%) with neither condition (Table 2). Loss of BAF250a expression was found to be 
significantly less frequent in CCC associated with adenofibroma alone than in CCC with 
endometriosis alone when analysed by Fisher’s exact test (p = 0.01). Because 18 patients had 
both endometriosis and adenofibroma, data were adjusted for endometriosis to clarify the 
correlation between adenofibroma and loss of BAF250a expression (Table 3). Univariate and 
multivariate analyses showed that the loss of BAF250a expression was less frequent in CCC 
with an adenofibromatous component. In 63 CCC patients with endometriosis, loss of 
BAF250a expression in the carcinomatous component occurred in 26 (55%) of 47 patients 
with endometriotic cysts contiguous with or adjacent to CCC and in 12 (75%) of 16 patients 
with endometriosis distant from CCC without cyst formation. Loss of BAF250a expression in 
CCC did not differ between the two types of endometriosis (p = 0.24, Fisher’s exact test). 
 Prognostic impact of BAF250a expression 
The 5-year progression-free survival rates in the 86 patients with pT1 CCC with and without 
loss of BAF250a expression were 82% and 79%, respectively. Kaplan–Meier analysis 
revealed no significant relationship between BAF250a immunoreactivity and progression-
free survival in pT1 CCC patients (p = 0.89, log-rank test) (Figure 2).  
 
Discussion 
In this study, we have shown that loss of BAF250a expression was significantly less frequent 
in adenofibroma-associated CCC than in endometriosis-associated CCC. This is the first 
report showing a genetic difference between adenofibroma-associated CCC and 
endometriosis-associated CCC. Our results suggest that the mutation in ARID1A, which 
encodes BAF250a, may not be as strongly associated with the development of adenofibroma-
related CCC as it is with endometriosis-related CCC, and that the role of ARID1A in 
carcinogenesis may differ between the two groups. We observed a loss of BAF250a 
expression in only 28% in adenofibroma-related CCC cases, indicating that another non-
ARID1A genetic aberration might underlie this condition. In contrast, loss of BAF250a 
expression in CCC with endometriosis was observed in 67% of the patients, consistent with 
previous studies.2, 21, 23 This indicates that the ARID1A mutation plays an important role in the 
development of CCC derived from endometriosis. Furthermore, the high frequency of 
ARID1A mutations in our study, as well as in earlier reports, and in ovarian endometrioid 
adenocarcinoma but not in high-grade serous carcinoma2, 3 suggests that ARID1A mutations 
might be associated with carcinomas related to endometriosis. In evaluating BAF250a 
immunostaining, we use the total score defined as percentage positivity score × staining 
intensity score ranging from 0 to 9.1, 20 Cells without ARID1A mutations, including normal 
cells, are expected to show positive staining for BAF250a. We considered ‘loss of BAF250a 
expression’ as significant decreases in staining intensity and in percentage of stained cells, 
and used the cut off index as a score of 4 or less to avoid overestimating the loss of BAF250a 
expression. We believe our evaluation method is justifiable, given that our result of BAF250a 
expression in CCC with endometriosis was consistent with that of published studies.2, 21- 23 
In our study, loss of BAF250a expression was not observed in the adenofibromatous 
component in any of the cases studied. This implies that ARID1A mutations do not occur in 
these putative precursor lesions and are not early events in adenofibroma-related CCC. This 
is in conflict with the findings of Yamamoto et al., who reported the loss of BAF250a 
expression in six of 14 cases of CCC associated with adenofibroma; benign (three of three), 
and borderline (six of six) clear cell adenofibroma components adjacent to carcinoma were 
found to lack BAF250a expression.23 A possible reason for the discrepancy between our 
results and those of Yamamoto et al. is the difference in the criteria used for adenofibroma 
diagnosis. Diagnostic criteria for the distinction between clear cell adenofibroma and 
borderline adenofibroma, and between borderline adenofibroma and CCC, have not been 
firmly established.15-17 Although we only designated cases as adenofibroma when tubules 
with minimal nuclear atypia were present, we occasionally observed a few tubules with 
moderate atypia mixed with tubules of carcinoma in the abundant fibrous stroma of 
adenofibroma-related CCC. In these cases, we considered the lesion to be part of the 
carcinoma and thus did not include it as an adenofibroma component.  
There have been several reports of loss of BAF250a expression not only in carcinoma 
but also in endometriosis and atypical endometriosis.2, 21-23 According to these reports, an 
ARID1A mutation occurred in atypical endometriosis before the development of carcinoma, 
and it was an early event in the malignant transformation of ovarian endometriosis. In the 
present study, we were not able to identify foci of atypical endometriosis in any of the cases 
included. Moreover, in contrast to some previous reports,21-23 the endometriotic component 
did not show loss of BAF250a expression in our study, perhaps owing to differences in the 
histological features of endometriotic lesions and experimental protocols. In our study, we 
included endometriosis associated with carcinoma, regardless of location and size. In most of 
our endometriosis patients, endometriotic lesions were subtle, often with a limited number of 
epithelial cells present. In studies by Ayhan et al. and Yamamoto et al., loss of BAF250a 
expression was observed in the epithelial cells of endometriotic lesions but not in endometrial 
stromal cells.21, 23 Thus, it is possible that in our patients, the epithelial cells of some 
endometriotic lesions had indeed lost BAF250a expression, but this could not be detected 
because of epithelial exfoliation. Alternatively, methodological attributes for these 
discrepancies might include differences in the antibodies, antibody dilutions, and 
immunohistochemical assessment methods used. To conclude whether ARID1A mutation 
occurs in conventional endometriosis and is an early event during malignant transformation 
of ovarian endometriosis, larger studies and additional methods such as DNA or RNA 
sequencing analysis2, 11 are needed.  
There are conflicting reports concerning the prognostic value of BAF250a expression in 
CCC. No prognostic impact of the loss of BAF250a expression was detected for pT1 CCC 
cases in our study. Maeda et al. reported no significant difference in overall survival in 121 
cases of CCC with or without loss of BAF250a expression.11 In contrast, Katagiri et al. 
reported that CCC patients showing loss of BAF250a expression had a shorter progression-
free interval than those with normal levels of BAF250a.24 Both these studies included CCC 
cases of all stages (FIGO stages III/IV in 31 of 121 cases and 15 of 60 cases in the former and 
latter studies, respectively), and that of Katagiri et al. included 12 of 60 cases with residual 
tumours of ≥2 cm, whereas in the present study, we included pT1 CCC cases only. It is 
possible that loss of BAF250a expression may be a prognostic factor in advanced-stage CCC; 
however, further in-depth studies are required to validate this concept.  
In conclusion, we identified a genetic difference in the carcinogenesis pathways of 
adenofibroma-related and endometriosis-related CCC by revealing that loss of BAF250a 
expression was significantly less frequent in adenofibroma-related CCC than in 
endometriosis-related CCC. Our results suggest that other non-ARID1A genetic aberrations 
might underlie adenofibroma-related CCC. We expect that our results might aid in the 
discovery of such mutations. Patients with CCC are resistant to currently available cytotoxic 
drugs. Therefore, another implication of our present findings is the possibility of 
individualization of CCC treatment once drugs targeting ARID1A are developed.  
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Table 1. Clinicopathological features of 93 ovarian clear cell carcinomas and loss of 
BAF250a expression (#1NX, lymphadenectomy not performed) 
Parameters n Loss of BAF250a expression (%) 
Total 93 50 (54)  
Mean age [years (range)] 56 (32–84)  
Tumour infiltration   
T1a 27 11 (41) 
T1b 1 1 (100) 
T1c 58 33 (57) 
T2a 0 0 (0) 
T2b 0 0 (0) 
T2c 5 3 (60) 
T3a 1 1 (100) 
T3b 0 0 (0) 
T3c 1 1 (100) 
Lymph node metastasis   
N0 51 31 (61) 
N1 1 0 (0) 
NX#1 41 19 (46) 
Received adjuvant chemotherapy   
Yes 80 48 (60) 
No 13 2 (15) 
Recurrence   
Yes 20 12 (60) 
No 73 38 (52) 
Table 2. Loss of BAF250a expression in carcinoma, adenofibroma, and endometriosis 
   Loss of BAF250a expression 
Associated lesion No. of cases   Adenofibroma Endometriosis Carcinoma 
Adenofibroma+/Endometriosis+ 18  0 (0%) 0 (0%) 8 (44%) 
Adenofibroma+/Endometriosis- 18  0 (0%) - 5 (28%)* 
Adenofibroma-/Endometriosis+ 45  - 0 (0%) 30 (67%)* 
Adenofibroma-/Endometriosis- 12   - - 7 (58%) 
*p = 0.01, Fisher’s exact test 
  
Table 3. Univariate and multivariate analysis of loss of BAF250a expression in carcinoma 
associated with adenofibroma and endometriosis 
 
 
 
 
 
 
 
 
 
 
 
 
        Univariate analysis   Multivariate analysis 
Associated 
lesion  
No. of 
cases 
No. of cases 
with loss of 
BAF250a 
expression in 
carcinoma 
  
Odds 
ratio 
95% CI p-value   
Odds 
ratio 
95% CI p-value 
Adenofibroma+ 36 13 (36%)  0.3 0.1–0.8 0.01  0.3 0.1–0.9 0.03 
Endometriosis+ 63 38 (60%)   0.6 0.2–1.1 0.10   1.8 0.7–4.6 0.25 
Figure 1. Representative histological features (A–D; hematoxylin and eosin staining) and 
BAF250a immunostaining (E–H) of clear cell carcinoma (CCC) and associated adenofibroma 
or endometriosis (×100). (A,B) CCC associated with adenofibroma. (C,D) CCC associated 
with endometriosis. (E) BAF250a expression is retained in both CCC and adenofibroma. (F) 
BAF250a expression is lost in CCC but retained in adenofibroma. (G) BAF250a expression is 
retained in both CCC and endometriosis. (H) BAF250a expression is lost in CCC but retained 
in endometriosis. 
  
Figure 2. Kaplan–Meier curves of progression-free survival and BAF250a expression in 
patients with pT1 cancer. 
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